Medtronic is no longer buying EOFlow, a Korean maker of wearable insulin pumps. The news comes three months after Insulet, EOFlow’s rival, filed a lawsuit accusing the company of stealing trade secrets.
In a filing with the Securities and Exchange Commission late Wednesday, Medtronic announced its cancellation of the deal. The filing is vague, citing “multiple breaches under the agreements” that allow Medtronic to renege. The device giant first announced the acquisition in May for $738 million, giving the company its first tubeless pump.
“We continue to advance our organic efforts and we remain committed to bringing a patch pump to market that integrates our most advanced CGM platform and clinically proven Meal Detection Technology™ algorithm,” Janet Cho, a Medtronic spokesperson, wrote to STAT.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect